Damora Therapeutics, Inc. (DMRA)
Nasdaq · Healthcare · Biotechnology
$20.22−2.08%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.2B
- 52-week range
- $4.95 – $38.33
- 52-week change
- +15.23%
- EPS (trailing)
- −$0.25
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$210M
- Diluted EPS
- $3.98
From the company’s annual report on SEC EDGAR.
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Headquarters: Waltham, United States · 7 employees · damoratx.com